Press Releases on November 7, 2024 - EIN Presswire - Press Release Distribution Service

Published on November 7, 2024 - 21:01 GMT

Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to report financial results for the third …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on November 7, 2024 - 21:01 GMT

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE’24 Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated …

Distribution channels:

Published on November 7, 2024 - 21:01 GMT

Teknova Reports Third Quarter 2024 Financial Results

Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior year Company lowers 2024 total free cash outflow outlook to less than $16 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Nov. 07, …

Distribution channels:

Published on November 7, 2024 - 21:01 GMT

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating runway into the fourth quarter of 2026 SAN DIEGO, Nov. 07 …

Distribution channels:

Published on November 7, 2024 - 21:01 GMT

Gevo Reports Third Quarter 2024 Financial Results

ENGLEWOOD, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the third quarter 2024 and recent corporate highlights. Recent Corporate Highlights Net-Zero 1 …

Distribution channels:

Published on November 7, 2024 - 21:01 GMT

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active …

Distribution channels: Business & Economy, Technology ...

Published on November 7, 2024 - 21:01 GMT

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for …

Distribution channels: Business & Economy, Technology ...

Published on November 7, 2024 - 21:01 GMT

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for …

Distribution channels: Business & Economy, Technology ...

Published on November 7, 2024 - 21:01 GMT

Maravai LifeSciences Reports Third Quarter 2024 Financial Results

Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D SAN DIEGO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global …

Distribution channels:

Published on November 7, 2024 - 21:01 GMT

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated …

Distribution channels: Business & Economy, Technology ...

Published on November 7, 2024 - 21:01 GMT

Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early Q2’2025 First subject dosed with TX000045 (“TX45”) in APEX Phase 2 clinical trial in early October, with topline …

Distribution channels:

Published on November 7, 2024 - 21:01 GMT

Astec to participate in Baird’s 2024 Global Industrial Conference

CHATTANOOGA, Tenn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Astec Industries, Inc. (Nasdaq: ASTE) announced today it will participate in the Baird Global Industrial Conference on November 14, 2024. Jaco van der Merwe, President and Chief Executive Officer, Brian …

Distribution channels: Culture, Society & Lifestyle, Technology ...

Published on November 7, 2024 - 21:01 GMT

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

COPENHAGEN, Denmark, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2024 financial results and provide a business update on Thursday, November 14, 2024, after the close of the U.S. …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on November 7, 2024 - 21:00 GMT

Axalta Celebrates the Opening of its Global Headquarters in the Philadelphia Navy Yard

PHILADELPHIA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Axalta (NYSE: AXTA), a leading global coatings company, has announced its global headquarters at the Philadelphia Navy Yard, marked by a ceremonial ribbon-cutting and an employee appreciation event. This …

Distribution channels: Chemical Industry, Media, Advertising & PR ...

Published on November 7, 2024 - 21:00 GMT

authID Reports Financial and Operating Results for the Third Quarter Ended September 30, 2024

DENVER, Nov. 07, 2024 (GLOBE NEWSWIRE) -- authID® (Nasdaq: AUID) (“authID”), a leading provider of secure identity verification and authentication solutions, today reported financial and operating results for the third quarter and nine months ended …

Distribution channels: Business & Economy, IT Industry ...

Published on November 7, 2024 - 21:00 GMT

MYNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Mynaric AG Investors with Substantial Losses Have ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mynaric AG (“Mynaric” or “the Company”) ( …

Distribution channels: Consumer Goods, Law ...

Published on November 7, 2024 - 21:00 GMT

MGX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or “the Company …

Distribution channels: Consumer Goods, Law ...

Published on November 7, 2024 - 21:00 GMT

IREN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iris Energy Limited Investors with Substantial Losses Have ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iris Energy Limited (“Iris Energy” or “the …

Distribution channels: Consumer Goods, Law ...

Published on November 7, 2024 - 21:00 GMT

EW INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Edwards Lifesciences Corporation Investors with Substantial ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards” …

Distribution channels: Consumer Goods, Law ...

Published on November 7, 2024 - 21:00 GMT

ELAN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elanco Animal Health Incorporated Investors with Substantial ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” …

Distribution channels: Consumer Goods, Law ...